Federal Register / Vol. 83, No. 140 / Friday, July 20, 2018 / Notices 34583 

proposing to relocate and consolidate its 

Cincinnati-based functions and 

personnel (approximately 550 

employees) currently housed at the 

three existing campuses to a new, 

consolidated campus in Cincinnati. 

Potential locations for the proposed 

new campus were identified through a 

comprehensive site selection process 

conducted by GSA on behalf of CDC. In 

June 2016, GSA issued a Request for 

Expressions of Interest (REOI) seeking 

potential sites capable of 

accommodating the proposed new 

campus. In response to the REOI, GSA 

received seven expressions of interest. 

Following an assessment of each site, 

GSA found that only one site qualified 

for further consideration (The Site). The 

Site encompasses all land between 

Martin Luther King Drive East to the 

south, Harvey Avenue to the west, 

Ridgeway Avenue to the north, and 

Reading Road to the east in Cincinnati, 

Ohio. 

Under NEPA, as implemented by CEQ 

Regulations (40 CFR parts 1500–1508), 

Federal agencies are required to 

evaluate the environmental effects of 

their proposed actions and a range of 

reasonable alternatives to the proposed 

action before making a decision. On 

February 9, 2018, in accordance with 

NEPA, CDC published a Notice of 

Availability announcing that a Draft EIS 

for the proposed acquisition and 

campus consolidation had been 

prepared (83 FR 5774). The Draft EIS 

evaluated the potential impacts of two 

alternatives: The Proposed Action 

Alternative (acquisition of the Site and 

construction of a new, consolidated 

CDC/NIOSH campus) and the No Action 

Alternative (continued use of the 

existing campuses for the foreseeable 

future). Impacts on the following 

resources were considered: Land use, 

zoning, and plans; community facilities; 

socioeconomics and environmental 

justice; utilities and infrastructure; 

visual quality; cultural resources; 

transportation; geology, topography, and 

soils; air quality; noise; and hazardous 

substances. 

Publication of the Draft EIS notice 

initiated a 45-day review period, which 

ended on March 26, 2018. During this 

period, CDC received comments from 

government agencies, a Native 

American tribe, and the public. These 

comments pertained to the proposed 

action in general; the accessibility of the 

proposed campus site for bicyclists; 

historic buildings; traffic and air quality 

impacts; sustainability; and the 

potential displacement of neighborhood 

residents. 

All comments were considered when 

preparing the Final EIS and responses to 

the comments are provided in the Final 

EIS. No comment required substantive 

revisions to the analyses presented in 

the Draft EIS or to the alternatives 

considered. The Final EIS identifies the 

Proposed Action Alternative as CDC’s 

Preferred Alternative. 

CDC will make a decision on whether 

to proceed with the proposed action 

after August 20, 2018. At that time, CDC 

will issue a Record of Decision 

documenting and explaining its 

decision based on the Final EIS. 

Questions on the Final EIS and the 

proposed action may be directed to: 

Harry Marsh, Architect, Office of Safety, 

Security and Asset Management 

(OSSAM), Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS–K80, Atlanta, Georgia 30329–4027, 

phone: (770) 488–8170, or email: cdccincinnati-eis@cdc.gov. 

Dated: July 16, 2018. 

Sandra Cashman, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–15410 Filed 7–19–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30 Day–18–0307] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request Gonococcal Isolate 

Surveillance Project to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on February 

5, 2018 to obtain comments from the 

public and affected agencies. The CDC 

received 2 non-substantive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Direct 

written comments and/or suggestions 

regarding the items contained in this 

notice to the Attention: CDC Desk 

Officer, Office of Management and 

Budget, 725 17th Street NW, 

Washington, DC 20503 or by fax to (202) 

395–5806. Provide written comments 

within 30 days of notice publication. 

Proposed Project 

Gonococcal Isolate Surveillance 

Project (0920–0307) (Exp. Date 02/28/ 

2019)—Revision—National Center for 

HIV, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Gonococcal Isolate Surveillance 

Project (GISP) was created in 1986 to 

monitor trends in antimicrobial 

susceptibilities of Neisseria gonorrhoeae 

strains in the United States. GISP 

continues to be a collaboration between 

different branches of the CDC Division 

of STD Prevention within the National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention (NCHHSTP), 

selected regional laboratories and 

selected state/local public health 

departments and their associated STD 

specialty care clinics in the U.S. 

National organizations, local 

jurisdictions and individuals use data 

collected in GISP to understand and 

prevent antibiotic resistance in N. 

gonorrhoeae. Data from GISP are used to 

establish a scientific basis for the 

selection of gonococcal therapies and to 

allow pro-active changes to treatment 

guidelines before widespread resistance 

and failures of treatment occur. To 

increase capacity to detect and monitor 

resistant gonorrhea and to improve the 

specificity of GISP, this revision is being 


daltland on DSKBBV9HB2PROD with NOTICES
34584 Federal Register / Vol. 83, No. 140 / Friday, July 20, 2018 / Notices 

submitted to include collection of 

additional isolates and data elements. 

In the current approval period, GISP 

isolates are only collected from males 

and include <4% of reported male 

gonorrhea cases in the United States. 

This relatively limited scope likely 

limits the speed with which new 

resistance patterns are found and with 

which public health officials can 

respond. Published data suggest that 

resistance in N. gonorrhoeae might 

develop initially in non-genital 

anatomic sites, such as the pharynx. It 

has also been hypothesized that 

susceptibility patterns may be different 

among women. Upon receiving OMB 

approval of the revision request, CDC 

plans to begin including isolates from 

the pharynx and other anatomic sites, as 

well as from women. These changes are 

expected to support public health efforts 

to detect and respond to resistance more 

quickly. 

GISP surveillance can also be 

strengthened by ensuring that GISP 

surveillance is only being conducted on 

N. gonorrhoeae and not on other similar 

bacteria. Neisseria meningitidis can 

cause clinical syndromes that are 

indistinguishable from gonorrhea. Using 

nucleic acid amplification tests (a more 

specific diagnostic test) in conjunction 

with bacterial culture from all anatomic 

sites can ensure that non-gonococcal 

bacteria are excluded from GISP data. 

This is expected to strengthen the 

accuracy and usefulness of GISP data. 

Historically, healthcare providers at 

approximately 30 participating sentinel 

sites (i.e., STD clinic or multiple STD 

clinics affiliated with a single public 

health department) obtain urethral N. 

gonorrhoeae isolates from the first 25 

men with urethral gonorrhea each 

month with occasional month-to-month 

variability. With this revision, we are 

now asking for a subset of sentinel sites 

(10 out of 30 sites) to conduct enhanced 

surveillance activities, collecting 

additional isolates (including from the 

pharynx, rectum, and cervix of exposed 

persons) with a limited number of 

additional data elements. We anticipate 

that approximately 50 additional 

isolates per month will be collected by 

each of these 10 sites (total of 

approximately 70 isolates per month per 

enhanced surveillance site). All isolates 

will be shipped each month to a 

regional laboratory for antimicrobial 

susceptibility testing. When isolates that 

appear to be bacteria other than N. 

gonorrhoeae are identified at one of the 

ten sentinel sites conducting enhanced 

surveillance, the isolate will be shipped 

to the regional laboratory and then to 

CDC. Based on informal discussions 

with current GISP sentinel sites, we 

anticipate that approximately 10 such 

isolates will be identified at each site 

per year. Sentinel sites that are not part 

of this small subset will continue to 

function as they already are. 

Under this revision, the data 

collection and reporting processes have 

been streamlined to minimize burden. 

All demographic/clinical data from the 

sentinel sites, and antimicrobial 

susceptibility testing results from the 

regional laboratories, will be submitted 

electronically (1) directly from the 

sentinel site to the GISP data manager 

at CDC through a secure data portal, (2) 

through a secure GISP-web based 

application, or (3) through the CDC 

Secure Access Management Services 

partner portal. To minimize burden, 

comma-separated values (csv) files that 

provide standardized structure of the 

electronic data are provided to sentinel 

sites and laboratories. Additionally, to 

further minimize burden, the regional 

laboratories will be able to extract 

electronic data from electronic 

laboratory information systems instead 

of hand entering data and will no longer 

be required to report control strain 

testing results. 

This project will not collect name, 

social security number, or date of birth. 

A Patient ID, a unique patient identifier 

assigned by the site that allows for 

linking of multiple isolates from a single 

person at a single clinic visit and across 

multiple clinic visits, is requested and 

will be provided to CDC for purposes of 

enhanced surveillance. Sensitive 

information such as sex of sex partners, 

HIV status, sex work exposure, and 

injection drug use are collected. Patient 

data are obtained through review of 

medical records by the clinic staff and 

included in collection reporting of 

demographic/clinical information. All 

personally identifiable information (PII) 

is retained by the STD clinics that 

treated the patient and is not recorded 

with data sent to CDC or regional 

laboratories. At sites where enhanced 

surveillance will not occur isolates are 

collected from patients as part of their 

routine care when a gonorrhea infection 

is suspected. The electronic GISP 

database is stored on the CDC 

mainframe computer and only approved 

Division of STD Prevention (DSTDP) 

staff have access rights to the data. As 

part of the revision, we will continue to 

systematically identify the risks and 

potential effects of collecting, 

maintaining, and disseminating PII and 

to examine and evaluate alternative 

processes for handling that information 

to mitigate potential privacy risks and 

risks to confidentiality. 

The CDC has designated N. 

gonorrhoeae as one of three ‘‘urgent’’ 

antibiotic resistance threats in the 

United States. The CDC is requesting a 

three-year OMB approval for this 

revision, which directly responds to the 

National Strategy for Combating 

Antibiotic Resistant Bacteria by 

improving and strengthening 

surveillance of antimicrobial resistance 

through GISP. This GISP data can help 

monitor and evaluate the effectiveness 

of public health interventions 

conducted to support the National 

Strategy for Combating AntibioticResistant Bacteria. Sentinel sites and 

regional laboratories voluntarily apply 

to participate in the GISP cooperative 

agreement program. Once funded, 

participation in the GISP information 

collection and isolate processing plan is 

required. The total estimated annualized 

burden hours are 11,376. There are no 

costs to respondents other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondents Form name Number of respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Sentinel site conducting core surveillance ..... Demographic/Clinical Data ............................. 20 240 11/60 

Sentinel site conducting enhanced surveillance.Demographic/Clinical Data ............................. 10 840 12/60 

Regional laboratory ......................................... Antimicrobial Susceptibility Testing Results .. 4 3,300 40/60 

Regional laboratory ......................................... Control Strain Susceptibility Testing .............. 4 48 5/60 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 140 / Friday, July 20, 2018 / Notices 34585 

Jeffrey M. Zirger, 

Acting Chief, Information Collection Review 

Office, Office of Scientific Integrity, Office 

of the Associate Director for Science, Office 

of the Director, Centers for Disease Control 

and Prevention. 

[FR Doc. 2018–15525 Filed 7–19–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–18–18AMQ; Docket No. CDC–2018– 

0061] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Assessing impact of the NIOSH 

research. The goal of the generic 

information collection request is to 

improve the ability of NIOSH to assess 

and demonstrate the extent to which its 

various research efforts are likely to or 

have led to improvements in workplace 

safety and health. 

DATES: CDC must receive written 

comments on or before September 18, 

2018. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2018– 

0061 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

Assessing impact of the NIOSH 

research—New—National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The National Institute for 

Occupational Safety and Health 

(NIOSH) is responsible for conducting 

research and making recommendations 

to prevent worker injury and illness, as 

authorized in Section 20(a)(1) of the 

Occupational Safety and Health Act (29 

U.S.C. 669). NIOSH is strongly 

committed to program evaluation as a 

way to maximize its contributions to 

improved occupational safety and 

health. NIOSH is requesting a new 

generic information collection request 

for a three-year period that will support 

the timely information collection 

needed for upcoming program 

evaluation activities, such as external 

reviews of NIOSH research programs 

(which fulfill a Government 

Performance and Results Act (GPRA) 

requirement, studies to understand the 

economic value of NIOSH research, 

process evaluations of NIOSH programs, 

and evaluations of large research 

projects. NIOSH needs to collect 

information about research 

dissemination and achieved outcomes 

from key audiences (grantees, potential 

NIOSH research users and relevant 

safety and health experts) for 

accountability and program 

improvement purposes. NIOSH is 

specifically interested in assessing 

intermediate outcomes—the use of 

NIOSH research products and findings 

by external stakeholders and partners to 

improve safety and health—as evidence 

of research impact. Being able to collect 

information on intermediate outcomes 

from grantees, as well as past, present 

and potential future users of NIOSH 

research would allow us to provide 

more robust evidence of use or adoption 

of NIOSH research products or findings. 

The evaluation findings and 

recommendations from the various 

program evaluation activities described 

above will be used as an input for future 

direction of the programs and 

incorporated into analyses and reports 

to either investigate the value of 

NIOSH’s research, or improve program 

operations to maximize impact. Data 

will be collected through semistructured key informant interviews 

with grantees, potential or known users 

of NIOSH research and subject matter 

experts in safety and health. NIOSH 

estimates that 30 respondents will be 

involved in phone interviews, which 

would last between 30–60 minutes. 

However, participants might be 

burdened an additional hour reading the 

invitation email and providing relevant 

documents such as evidence of research 

impact. Therefore, the estimated burden 

for each participant is two hours. The 

total estimated burden is 60 hours. 

There is no cost to respondents other 

than their time. 


daltland on DSKBBV9HB2PROD with NOTICES